Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: Biological risk factors for infection according to time after transplantation

Clinical Infectious Diseases

Volumn 47, Issue 8, 2008, Pages 1041-1050

  Garcia Vidal, Carol ^a,d   Upton, Arlo ^a   Kirby, Katharine A ^a   Marr, Kieren A ^a,b,c,e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMPHOTERICIN B; CEFTAZIDIME; FERRITIN; FLUCONAZOLE; GANCICLOVIR; VANCOMYCIN;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLUS; CANDIDIASIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; FERRITIN BLOOD LEVEL; FEVER; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; IMMUNOPATHOGENESIS; INCIDENCE; INFECTION; INFECTION RISK; INVASIVE MOLD INFECTION; IRON OVERLOAD; LUNG LAVAGE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MONOCYTOPENIA; MONOTHERAPY; NEUTROPENIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SPUTUM CULTURE; SURVIVAL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FUNGI; GRAFT VS HOST DISEASE; HISTOCOMPATIBILITY; HUMANS; INCIDENCE; IRON OVERLOAD; KAPLAN-MEIERS ESTIMATE; LEUKOPENIA; MALE; MIDDLE AGED; MYCOSES; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 53349157204     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/591969     Document Type: Article

References (32)

1. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358-66.
2. Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis 2003; 3:156-61.
3. Wingard JR. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant 1999; 5:55-68.
4. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-52.
5. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:1350-60.
6. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
7. Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr Opin Infect Dis 2003; 16:607-12.
8. Nucci M, Marr KA, Queiroz-Telles F, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38:1237-42.
9. Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102:827-33.
10. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29:15-9.
11. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34:115-21.
12. Maertens J, Demuynck H, Verbeken EK, et al. Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant 1999; 24:307-12.
13. Miceli MH, Dong L, Grazziutti ML, et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006; 37:857-64.
14. Kontoyiannis D, Wessel V, Bodey G, Rolston K. Zygomycosis in the 1990s in a tertiary care center. Clin Infect Dis 2000; 30:851-6.
15. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
16. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344:175-81.
17. Buckner CD, Clift RA, Appelbaum FR, et al. Effects of treatment regimens in patients allografted for acute and chronic myelogenous leukemia. Bone Marrow Transplant 1991; 7(Suppl 2):6-8.
18. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84:2036-43.
19. Nash RA, Pineiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 1996; 88:3634-41.
20. Brissot P, Bourel M, Herry D, et al. Assessment of liver iron content in 271 patients: a reevaluation of direct and indirect methods. Gastroenterology 1981; 80:557-65.
21. Dvorak CC, Steinbach WJ, Brown JM, Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005; 36:621-9.
22. + T cell responses to live and heat-inactivated Aspergillus fumigatus conidia. Infect Immun 2005; 73:7170-9.
23. Rivera A, Hohl T, Pamer EG. Immune responses to Aspergillus fumigatus infections. Biol Blood Marrow Transplant 2006; 12(Suppl 1):47-9.
24. Beck O, Topp MS, Koehl U, et al. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 2006; 107:2562-9.
25. Boeckh M, Nichols WG. Immunosuppressive effects of β-herpesviruses. Herpes 2003; 10:12-6.
26. Franke-Ullmann G, Pfortner C, Walter P, et al. Alteration of pulmonary macrophage function by respiratory syncytial virus infection in vitro. J Immunol 1995; 154:268-80.
27. Kauth M, Grage-Griebenow E, Rohde G, et al. Synergistically upregulated interleukin-10 production in cocultures of monocytes and T cells after stimulation with respiratory syncytial virus. Int Arch Allergy Immunol 2007; 142:116-26.
28. Philippe B, Ibrahim-Granet O, Prevost MC, et al. Killing of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates. Infect Immun 2003; 71:3034-42.
29. Brummer E, Kamberi M, Stevens DA. Regulation by granulocyte-macrophage colony-stimulating factor and/or steroids given in vivo of proinflammatory cytokine and chemokine production by bronchoalveolar macrophages in response to Aspergillus conidia. J Infect Dis 2003; 187:705-9.
30. Raghavan M, Marik PE. Anemia, allogenic blood transfusion, and immunomodulation in the critically ill. Chest 2005; 127:295-307.
31. Zaas A, Liao G, Chien J, et al. Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genetics 2008; 4:e1000101.
32. Bochud P, Chien J, Janer M, Marr K, Aderem A, Boeckh M. Donor's Toll-like receptor 4 haplotypes increase the incidence of invasive mould infections in hematopoietic stem cell transplant recipients. In: 46th International Conference for Antimicrobial Agents and Chemotherapy (San Francisco, CA). Washington, DC: American Society for Microbiology, 2006.